Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Barzilai Medical Center | OTHER |
| Rambam Health Care Campus | OTHER |
| Nazareth Hospital | OTHER |
Not provided
Not provided
Not provided
This is an open-label run-in followed by a randomized, double-blind drug treatment study of COVID-19 infected patients requiring inpatient hospital admission.
This is an open-label run-in followed by a randomized, double-blind drug treatment study of COVID-19 infected patients requiring inpatient hospital admission. Open-label patients will be matched at least 1:10 with observational retrospective Propensity score-matched (PSM) patients' medical files. The double-blinded step will be randomized 2:1 to daily Fenofibrate or placebo for 10 days or hospital discharge.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Fenofibrate + Usual Care | Experimental | Participants in this arm will receive the study drug, Fenofibrate, in combination with usual care. |
|
| Placebo + Usual Care | Placebo Comparator | Participants in this arm will receive placebo treatment, in combination with usual care. |
|
| Usual Care (Observetional) | No Intervention | Participants in this arm will receive the usual care and be compared by their medical records and laboratory results |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| TriCor® 145mg tablets | Drug | Fenofibrate; 145 mg daily (1/day); oral administration; 10 days |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Therapeutic Oxygen-Free Days | Outcome reported as the mean number of days participants in each arm did not require therapeutic oxygen usage during an in-patient hospital admission. | 14 days |
| Length of Hospital Stay | Outcome reported as the mean length of in-patient hospital stay (in days) for participants in each arm | 14 days |
| Viral Clearance by Nasopharyngeal Swab | Nasopharyngeal swabs will be collected every second day for the duration of study participation. Viral clearance is measured as fold change in viral genetic copies per mL | 14 days |
| Difference in Estimated P/F Ratio at 14 days | Outcome calculated from the partial pressure of oxygen or peripheral saturation of oxygen by pulse oximetry divided by the fraction of inspired oxygen (PaO2 or SaO2 : FiO2 ratio). PaO2 is preferentially used if available. | 14 days |
| Difference in Plasma Neutrophils at 14 days | Blood will be collected every second day for the duration of study participation. Difference will be calculated based on the first measurement after admission to the study. | 14 days |
| Difference in Plasma Lymphocytes at 14 days | Blood will be collected every second day for the duration of study participation. Difference will be calculated based on the first measurement after admission to the study. | 14 days |
| Difference in Plasma Monocytes at 14 days |
| Measure | Description | Time Frame |
|---|---|---|
| 14-Day Mortality | Outcome reported as the number of participants who have expired at 14 days post enrollment. | 14 days |
| Difference in Organ Injury Plasma markers at 14 days - Lactate | Blood will be collected every second day for the duration of study participation. Difference will be calculated based on the first measurement after admission to the study. |
| Measure | Description | Time Frame |
|---|---|---|
| Significant post-acute incident diagnoses after recovery at 28-days | Incident rate per 1000 at 28-days in hospitalized COVID-19 is ascertained from hospital admission until 28-days or end of follow-up. | 1 day |
| Significant post-acute incident diagnoses after recovery at 90-days |
Inclusion Criteria:
Presumptive positive laboratory test for SARS-CoV-2 based on local laboratory standard
Age greater than or equal to 18 years of age
Severe COVID-19, defined by:
AND o A respiratory SOFA >=1 and increased oxygen requirement compared to baseline among those on home O2, a blood oxygen saturation of 93% or less on room air, a ratio of the partial pressure of oxygen to the fraction of inspired oxygen (PaO2/FiO2) of less than 300 mm Hg, respiratory rate >30 breaths/min, or lung infiltrates >50% on chest CT
• Enrollment within 72 hours of presentation of hospital admission or within 72 hours of a positive test result, whichever is later
Exclusion Criteria:
Enrollment > 72 hours of admission order or positive test result, whichever is later
Admission to the hospital with a respiratory SOFA >=5 , Critical COVID-19, or Disease Severity Score >5 (requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or all)
Known hypersensitivity to fenofibrate
For female subjects:
Patient-reported history or electronic medical record history of kidney disease, defined as:
Acute pre-renal azotemia at the time of enrollment in the opinion of the investigator or bedside clinician
Most recent mean arterial blood pressure prior to enrollment <65 mmHg
Patient-reported history or electronic medical record history of severe liver disease, defined as:
Patient-reported history or electronic medical record history of gallbladder disease
Potassium >5.0 within 24 hours prior to enrollment unless a repeat value was <=5.0
Treatment with coumarin anticoagulants (e.g., Warfarin), immunosuppressants (e.g. cisplatin), bile acid resins, or sulfonylurea.
Inability to obtain informed consent from participant or legally authorized representative
Enrollment in another blinded randomized clinical trial for COVID
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Yaakov Nahmias, PhD | Contact | +972-2-5494640 | ynahmias@cs.huji.ac.il | |
| Avner Ehrlich | Contact | +972-54-3181422 | avner.ehrlich@mail.huji.ac.il |
| Name | Affiliation | Role |
|---|---|---|
| Shlomo Mayaan, MD | Barzilai Medical Center | Principal Investigator |
| Mahram Nassar, MD | Barzilai Medical Center | Study Director |
| Yaakov Nahmias, PhD |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Barzilai Medical Center | Recruiting | Ashkelon | 7830604 | Israel |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32242089 | Background | Bornstein SR, Dalan R, Hopkins D, Mingrone G, Boehm BO. Endocrine and metabolic link to coronavirus infection. Nat Rev Endocrinol. 2020 Jun;16(6):297-298. doi: 10.1038/s41574-020-0353-9. | |
| Background | Ehrlich, A., Uhl, S., Ioannidis, K., Hofree, M., tenOever, B., and Nahmias, Y. (2020). The SARS-CoV-2 Transcriptional Metabolic Signature in Lung Epithelium. SSRN Electronic Journal. | ||
| 20580052 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D012128 | Respiratory Distress Syndrome |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D011345 | Fenofibrate |
| ID | Term |
|---|---|
| D058607 | Fibric Acids |
| D058610 | Isobutyrates |
| D002087 | Butyrates |
| D000144 | Acids, Acyclic |
Not provided
Not provided
An interventional single-arm non-randomized pilot study in 15 patients, followed by an Interventional double-blinded randomized quadruple masked study in 40 patients.
Not provided
Not provided
Not provided
| Placebo | Other | Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration |
|
| Usual care | Other | All participants will otherwise receive usual medical care |
|
Blood will be collected every second day for the duration of study participation. Difference will be calculated based on the first measurement after admission to the study. |
| 14 days |
| Difference in Plasma C-Reactive Protein (CRP) at 14 days | Blood will be collected every second day for the duration of study participation. Difference will be calculated based on the first measurement after admission to the study. | 14 days |
| Difference in Plasma IL-6 at 14 days | Blood will be collected every second day for the duration of study participation. Difference will be calculated based on the first measurement after admission to the study. | 14 days |
| Difference in Plasma Procalcitonin (PCT) at 14 days | Blood will be collected every second day for the duration of study participation. Difference will be calculated based on the first measurement after admission to the study. | 14 days |
| Difference in Plasma Ferritin at 14 days | Blood will be collected every second day for the duration of study participation. Difference will be calculated based on the first measurement after admission to the study. | 14 days |
| Difference in NLR (Neutrophils to Lymphocytes Ratio) at 14 days | Blood will be collected every second day for the duration of study participation. Difference will be calculated based on the first measurement after admission to the study. | 14 days |
| 14 days |
| Difference in Organ Injury Plasma markers at 14 days - Cardiac Troponin (TRO) | Blood will be collected every second day for the duration of study participation. Difference will be calculated based on the first measurement after admission to the study. | 14 days |
| Difference in Organ Injury Plasma markers at 14 days - Creatine Kinase (CK) | Blood will be collected every second day for the duration of study participation. Difference will be calculated based on the first measurement after admission to the study. | 14 days |
| Difference in Organ Injury Plasma markers at 14 days - Alanine Aminotransferase (ALT) | Blood will be collected every second day for the duration of study participation. Difference will be calculated based on the first measurement after admission to the study. | 14 days |
| Difference in Organ Injury Plasma markers at 14 days - Alkaline Phosphatase (ALP) | Blood will be collected every second day for the duration of study participation. Difference will be calculated based on the first measurement after admission to the study. | 14 days |
| Difference in Organ Injury Plasma markers at 14 days - D-dimer | Blood will be collected every second day for the duration of study participation. Difference will be calculated based on the first measurement after admission to the study. | 14 days |
| Difference in Organ Injury Plasma markers at 14 days - Platelets (PLT) | Blood will be collected every second day for the duration of study participation. Difference will be calculated based on the first measurement after admission to the study. | 14 days |
| Number of Abnormal Biomarker Days - D-dimer | Outcome reported as the mean number of days participants in each arm had abnormal plasma levels. | 14 days |
| Number of Abnormal Biomarker Days - Neutrophils | Outcome reported as the mean number of days participants in each arm had abnormal plasma levels. | 14 days |
| Number of Abnormal Biomarker Days - Lymphocytes | Outcome reported as the mean number of days participants in each arm had abnormal plasma levels. | 14 days |
| Number of Abnormal Biomarker Days - Platelets (PLT) | Outcome reported as the mean number of days participants in each arm had abnormal plasma levels. | 14 days |
| Number of Abnormal Biomarker Days - Monocytes | Outcome reported as the mean number of days participants in each arm had abnormal plasma levels. | 14 days |
| Number of Abnormal Biomarker Days - C-Reactive Protein (CRP) | Outcome reported as the mean number of days participants in each arm had abnormal plasma levels. | 14 days |
| Number of Abnormal Biomarker Days - IL-6 | Outcome reported as the mean number of days participants in each arm had 2 or more abnormal plasma levels. | 14 days |
| Number of Abnormal Biomarker Days - Procalcitonin (PCT) | Outcome reported as the mean number of days participants in each arm had abnormal plasma levels. | 14 days |
| Number of Abnormal Biomarker Days - Lactate | Outcome reported as the mean number of days participants in each arm had abnormal plasma levels. | 14 days |
| Number of Abnormal Biomarker Days - Cardiac Troponin (TRO) | Outcome reported as the mean number of days participants in each arm had abnormal plasma levels. | 14 days |
| Number of Abnormal Biomarker Days - Creatine Kinase (CK) | Outcome reported as the mean number of days participants in each arm had abnormal plasma levels. | 14 days |
| Number of Abnormal Biomarker Days - Alanine Aminotransferase (ALT) | Outcome reported as the mean number of days participants in each arm had abnormal plasma levels. | 14 days |
| Number of Abnormal Biomarker Days - Alkaline Phosphatase (ALP) | Outcome reported as the mean number of days participants in each arm had abnormal plasma levels. | 14 days |
| Number of Abnormal Biomarker Days - Ferritin | Outcome reported as the mean number of days participants in each arm had abnormal plasma levels. | 14 days |
| Difference in Oxygenation at 14 days | PaO2 or SaO2 and FiO2. Partial pressure of oxygen or peripheral saturation of oxygen by pulse oximetry. FiO₂ is estimated from oxygen flow/delivery rates | 14 days |
| Difference in Estimated PEEP adjusted P/F Ratio at 14 days | Outcome calculated from the partial pressure of oxygen or peripheral saturation of oxygen by pulse oximetry divided by the fraction of inspired oxygen (PaO2 or SaO2 : FiO2 ratio) and Expiratory Pressure. | 14 days |
| Daily Hypotensive Episodes | Outcome reported as the mean number of daily hypotensive episodes (MAP < 65 mmHg) prompting intervention (indicated by a fluid bolus >=500 mL, new treatment with pressures, increase in 50% pressure or fluid rate) per participant in each arm. | 14 days |
| Hypotension Requiring Vasopressors | Outcome reported as the number of participants in each arm requiring the use of vasopressors for hypotension. | 14 days |
| Acute Kidney Injury | Outcome reported as the number of participants in each arm who experience acute kidney injury as defined by the Kidney Disease Improving Global Outcomes (KDIGO) guidelines: Increase in serum creatinine by 0.3mg/dL or more within 48 hours OR Increase in serum creatinine to 1.5 times baseline or more within the last 7 days OR Urine output less than 0.5 mL/kg/h for 6 hours. | 14 days |
| Sequential Organ Failure Assessment (SOFA) Total Score | The SOFA assessment is used to track a person's risk status during stay in the Intensive Care Unit (ICU). The score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal, and neurological systems. Each organ system is assigned a point value from 0 (normal) to 4 (high degree of dysfunction/failure). Total score is calculated by entering patient data into a SOFA calculator, a widely available software. Total scores range from 0-24, with higher scores indicating greater risk of mortality. | 14 days |
| Oxygen Saturation / Fractional Inhaled Oxygen (F/S) | Oxygen saturation (percent) is measured by pulse oximeter. Fraction of inspired oxygen (FiO2) (unitless) is the volumetric fraction of oxygen to other gases in respiratory support. The F/S ratio is unitless. | 14 days |
| 28-Day Mortality | Outcome reported as the number of participants who have expired at 28 days post enrollment. | 28 days |
| 90-Day Mortality | Outcome reported as the number of participants who have expired at 90 days post enrollment. | 90 days |
| ICU Admission | Outcome reported as the number of participants in each arm who require admission to the Intensive Care Unit (ICU). | 14 days |
| Number of Ventilator-Free Days | Outcome reported as the mean number of days participants in each arm did not require mechanical ventilation during an in-patient hospital admission. | 14 days |
| Number of Vasopressor-Free Days | Outcome reported as the mean number of days participants in each arm did not require vasopressor usage during an in-patient hospital admission. | 14 days |
| Length of ICU Stay | Outcome reported as the mean length of stay (in days) in the Intensive Care Unit (ICU) for participants in each arm. | 14 days |
| Incidence of Respiratory Failure | Outcome reported as the number of participants requiring BiPAP OR high flow nasal cannula OR mechanical ventilation OR extracorporeal membranous oxygenation (ECMO) utilization during in-patient hospital care in each arm. | 14 days |
| Change in PROMIS Dyspnea Functional Limitations | The PROMIS Dyspnea (shortness of breath) item banks and pools assess self-reported Functional Limitations, Severity, Activity Motivation, Activity Requirements, Airborne Exposure, Assistant Devices Resources, Characteristics, Emotional Response, Task Avoidance and Time Extension as they related to dyspnea. In the 33-item Functional Limitations bank, 33 daily activities are rated in terms of degree of difficulty while engaging in the activity over the past 7 days (0 = no difficulty, 1 = a little difficulty, 2 = some difficulty, 3 = much difficulty). Total scores range from 0 to 99, with higher scores reflecting greater functional limitations. | 14 days |
| Change in PROMIS Dyspnea Severity | The PROMIS Dyspnea (shortness of breath) item banks and pools assess self-reported Functional Limitations, Severity, Activity Motivation, Activity Requirements, Airborne Exposure, Assistant Devices Resources, Characteristics, Emotional Response, Task Avoidance and Time Extension as they related to dyspnea. The 33-item Severity bank assesses the severity of difficulty breathing during various specific activities (the same 33 activities assessed in Dyspnea Functional Limitations). Each activity is rated in terms of degree of dyspnea (0 = no shortness of breath, 1 = mildly short of breath, 2 = moderately short of breath, 3 = severely short of breath) while engaging in the activity over the past 7 days. Total scores range from 0 to 99 with higher scores reflecting greater levels of dyspnea during daily activity. | 14 days |
| Disease Severity Rating | Outcome reported as the number of participants in each arm who fall into each of 7 categories. Lower scores indicate greater condition severity. The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities. | 14 days |
| Viral Load by Nasopharyngeal Swab | Nasopharyngeal swabs will be collected every fourth day for the duration of study participation. Viral load is measured as number of viral genetic copies per mL. | 14 days |
| Viral Load by Blood | Blood will be collected every third day for viral load assessment for the duration of study participation. Viral load is measured as number of viral genetic copies per mL. | 14 days |
| Viral Clearance by Blood | Blood will be collected every third day for viral load assessment for the duration of study participation. clearance is measured as fold change in viral genetic copies per mL. | 14 days |
| Abnormal Biomarkers after recovery - D-dimer | Outcome reported as the mean number of days participants in each arm had abnormal plasma levels. | 1 day |
| Abnormal Biomarkers after recovery - Neutrophils | Outcome reported as the mean number of days participants in each arm had abnormal plasma levels. | 1 day |
| Abnormal Biomarkers after recovery - Lymphocytes | Outcome reported as the mean number of days participants in each arm had abnormal plasma levels. | 1 day |
| Abnormal Biomarkers after recovery - Platelets (PLT) | Outcome reported as the mean number of days participants in each arm had abnormal plasma levels. | 1 day |
| Abnormal Biomarkers after recovery - Monocytes | Outcome reported as the mean number of days participants in each arm had abnormal plasma levels. | 1 day |
| Abnormal Biomarkers after recovery - C-Reactive Protein (CRP) | Outcome reported as the mean number of days participants in each arm had abnormal plasma levels. | 1 day |
| Abnormal Biomarkers after recovery - IL-6 | Outcome reported as the mean number of days participants in each arm had abnormal plasma levels. | 1 day |
| Abnormal Biomarkers after recovery - Procalcitonin (PCT) | Outcome reported as the mean number of days participants in each arm had abnormal plasma levels. | 1 day |
| Abnormal Biomarkers after recovery - Lactate | Outcome reported as the mean number of days participants in each arm had abnormal plasma levels. | 1 day |
| Abnormal Biomarkers after recovery - Cardiac Troponin (TRO) | Outcome reported as the mean number of days participants in each arm had abnormal plasma levels. | 1 day |
| Abnormal Biomarkers after recovery - Creatine Kinase (CK) | Outcome reported as the mean number of days participants in each arm had abnormal plasma levels. | 1 day |
| Abnormal Biomarkers after recovery - Alanine Aminotransferase (ALT) | Outcome reported as the mean number of days participants in each arm had abnormal plasma levels. | 1 day |
| Abnormal Biomarkers after recovery - Alkaline Phosphatase (ALP) | Outcome reported as the mean number of days participants in each arm had abnormal plasma levels. | 1 day |
| Abnormal Biomarkers after recovery - Ferritin | Outcome reported as the mean number of days participants in each arm had abnormal plasma levels. | 1 day |
| Abnormal Oxygenation after recovery | Outcome reported as the mean number of participants in each arm had abnormal PaO2 or SaO2 and FiO2 levels at the end of quarantine period. Partial pressure of oxygen or peripheral saturation of oxygen by pulse oximetry. FiO₂ is estimated from oxygen flow/delivery rates | 1 day |
| PROMIS Dyspnea Functional Limitations after recovery | The PROMIS Dyspnea (shortness of breath) item banks and pools assess self-reported Functional Limitations, Severity, Activity Motivation, Activity Requirements, Airborne Exposure, Assistant Devices Resources, Characteristics, Emotional Response, Task Avoidance and Time Extension as they related to dyspnea. In the 33-item Functional Limitations bank, 33 daily activities are rated in terms of degree of difficulty while engaging in the activity over the past 7 days (0 = no difficulty, 1 = a little difficulty, 2 = some difficulty, 3 = much difficulty). Total scores range from 0 to 99, with higher scores reflecting greater functional limitations. Measured at the end of quarantine period. | 1 day |
| PROMIS Dyspnea Severity after recovery | The PROMIS Dyspnea (shortness of breath) item banks and pools assess self-reported Functional Limitations, Severity, Activity Motivation, Activity Requirements, Airborne Exposure, Assistant Devices Resources, Characteristics, Emotional Response, Task Avoidance and Time Extension as they related to dyspnea. The 33-item Severity bank assesses the severity of difficulty breathing during various specific activities (the same 33 activities assessed in Dyspnea Functional Limitations). Each activity is rated in terms of degree of dyspnea (0 = no shortness of breath, 1 = mildly short of breath, 2 = moderately short of breath, 3 = severely short of breath) while engaging in the activity over the past 7 days. Total scores range from 0 to 99 with higher scores reflecting greater levels of dyspnea during daily activity. Measured at the end of quarantine period. | 1 day |
Incident rate per 1000 at 90-days in hospitalized COVID-19 is ascertained from hospital admission until 90-days or end of follow-up. |
| 1 day |
| Significant post-acute incident diagnoses after recovery at 6-months | Incident rate per 1000 at 6-months in hospitalized COVID-19 is ascertained from hospital admission until 6-months or end of follow-up. | 1 day |
| Hebrew University of Jerusalem |
| Principal Investigator |
| Rambam Health Care Campus | Recruiting | Haifa | Israel |
|
| Nazareth Hospital EMMS | Recruiting | Nazareth | Israel |
|
| Background |
| McBride CE, Machamer CE. Palmitoylation of SARS-CoV S protein is necessary for partitioning into detergent-resistant membranes and cell-cell fusion but not interaction with M protein. Virology. 2010 Sep 15;405(1):139-48. doi: 10.1016/j.virol.2010.05.031. Epub 2010 Jul 1. |
| 28831119 | Background | Wu Q, Zhou L, Sun X, Yan Z, Hu C, Wu J, Xu L, Li X, Liu H, Yin P, Li K, Zhao J, Li Y, Wang X, Li Y, Zhang Q, Xu G, Chen H. Altered Lipid Metabolism in Recovered SARS Patients Twelve Years after Infection. Sci Rep. 2017 Aug 22;7(1):9110. doi: 10.1038/s41598-017-09536-z. |
| 30654597 | Background | Yan B, Chu H, Yang D, Sze KH, Lai PM, Yuan S, Shuai H, Wang Y, Kao RY, Chan JF, Yuen KY. Characterization of the Lipidomic Profile of Human Coronavirus-Infected Cells: Implications for Lipid Metabolism Remodeling upon Coronavirus Replication. Viruses. 2019 Jan 16;11(1):73. doi: 10.3390/v11010073. |
| 19333547 | Background | Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010 Sep;47(3):193-9. doi: 10.1007/s00592-009-0109-4. Epub 2009 Mar 31. |
| 30631056 | Background | Yuan S, Chu H, Chan JF, Ye ZW, Wen L, Yan B, Lai PM, Tee KM, Huang J, Chen D, Li C, Zhao X, Yang D, Chiu MC, Yip C, Poon VK, Chan CC, Sze KH, Zhou J, Chan IH, Kok KH, To KK, Kao RY, Lau JY, Jin DY, Perlman S, Yuen KY. SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target. Nat Commun. 2019 Jan 10;10(1):120. doi: 10.1038/s41467-018-08015-x. |
| 32369736 | Background | Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, Lei F, Wang H, Xie J, Wang W, Li H, Zhang P, Song X, Chen X, Xiang M, Zhang C, Bai L, Xiang D, Chen MM, Liu Y, Yan Y, Liu M, Mao W, Zou J, Liu L, Chen G, Luo P, Xiao B, Zhang C, Zhang Z, Lu Z, Wang J, Lu H, Xia X, Wang D, Liao X, Peng G, Ye P, Yang J, Yuan Y, Huang X, Guo J, Zhang BH, Li H. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020 Jun 2;31(6):1068-1077.e3. doi: 10.1016/j.cmet.2020.04.021. Epub 2020 May 1. |
| 36705566 | Derived | Ehrlich A, Ioannidis K, Nasar M, Abu Alkian I, Daskal Y, Atari N, Kliker L, Rainy N, Hofree M, Shafran Tikva S, Houri I, Cicero A, Pavanello C, Sirtori CR, Cohen JB, Chirinos JA, Deutsch L, Cohen M, Gottlieb A, Bar-Chaim A, Shibolet O, Mandelboim M, Maayan SL, Nahmias Y. Efficacy and safety of metabolic interventions for the treatment of severe COVID-19: in vitro, observational, and non-randomized open-label interventional study. Elife. 2023 Jan 27;12:e79946. doi: 10.7554/eLife.79946. |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D012120 | Respiration Disorders |
| D002264 |
| Carboxylic Acids |
| D009930 | Organic Chemicals |
| D010647 | Phenyl Ethers |
| D004987 | Ethers |
| D001577 | Benzophenones |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D010636 | Phenols |
| D007659 | Ketones |